Deepan Chatterjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Deepan Chatterjee has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Dianna H. Huisman
Eppley Institute, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska
19 shared publications - Robert E. Lewis
University of Nebraska Medical Center
19 shared publications - Heidi M. Vieira
Department of Radiation Oncology University of Nebraska Medical Center Omaha Nebraska USA
18 shared publications - James W. Askew
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA
18 shared publications - Kurt W. Fisher
University of Nebraska Medical Center
18 shared publications - Robert A. Svoboda
Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska
17 shared publications
Latest Publications
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Data from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Small cell lung carcinoma (SCLC) tumors are heterogeneous, with a subpopulation of cells primed for tumor initiation. In this study, we show that kinase suppressor of Ras 2 (KSR2) promotes the self-renewal and clonogenicity of SCLC cells. KSR2 is a molecular scaffold that promotes Raf/MEK/ERK signaling. KSR2 is preferentially expressed in the ASCL1 subtype of SCLC (SCLC-A) tumors and is expressed in pulmonary neuroendocrine cells, one of the identified cells of origin for SCLC-A tumors. The expression of KSR2 in SCLC and pulmonary neuroendocrine cells was previously unrecognized and serves as a novel model for understanding the role of KSR2-dependent signaling in normal and malignant tissues. Disruption of KSR2 in SCLC-A cell lines inhibits the colony-forming ability of tumor-propagating cells in vitro and their tumor-initiating capacity in vivo. The effect of KSR2 depletion on self-renewal and clonogenicity is dependent on the interaction of KSR2 with ERK. These data indicate that the expression of KSR2 is an essential driver of SCLC-A tumor–propagating cell function and therefore may play a role in SCLC tumor initiation. These findings shed light on a novel effector promoting initiation of SCLC-A tumors and a potential subtype-specific therapeutic target.Implications:Manipulation of the molecular scaffold KSR2 in SCLC-A cells reveals its contribution to self-renewal, clonogenicity, and tumor initiation.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Small cell lung carcinoma (SCLC) tumors are heterogeneous, with a subpopulation of cells primed for tumor initiation. In this study, we show that kinase suppressor of Ras 2 (KSR2) promotes the self-renewal and clonogenicity of SCLC cells. KSR2 is a molecular scaffold that promotes Raf/MEK/ERK signaling. KSR2 is preferentially expressed in the ASCL1 subtype of SCLC (SCLC-A) tumors and is expressed in pulmonary neuroendocrine cells, one of the identified cells of origin for SCLC-A tumors. The expression of KSR2 in SCLC and pulmonary neuroendocrine cells was previously unrecognized and serves as a novel model for understanding the role of KSR2-dependent signaling in normal and malignant tissues. Disruption of KSR2 in SCLC-A cell lines inhibits the colony-forming ability of tumor-propagating cells in vitro and their tumor-initiating capacity in vivo. The effect of KSR2 depletion on self-renewal and clonogenicity is dependent on the interaction of KSR2 with ERK. These data indicate that the expression of KSR2 is an essential driver of SCLC-A tumor–propagating cell function and therefore may play a role in SCLC tumor initiation. These findings shed light on a novel effector promoting initiation of SCLC-A tumors and a potential subtype-specific therapeutic target.Implications:Manipulation of the molecular scaffold KSR2 in SCLC-A cells reveals its contribution to self-renewal, clonogenicity, and tumor initiation.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Table S2. KSR2 is preferentially expressed in human SCLC-A cell lines.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Table S2. KSR2 is preferentially expressed in human SCLC-A cell lines.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Table S4. Tumor formation in H209 in vivo ELDA.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Table S4. Tumor formation in H209 in vivo ELDA.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Table S3. Tumor formation in KP1 in vivo ELDA.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Table S3. Tumor formation in KP1 in vivo ELDA.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Figure S2. Proliferation, apoptosis, and subtype are not affected by KSR2 disruption in H209 tumor xenografts.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Figure S2. Proliferation, apoptosis, and subtype are not affected by KSR2 disruption in H209 tumor xenografts.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Figure S3. Inhibition of ERK phosphorylation does not affect TPC function.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Figure S3. Inhibition of ERK phosphorylation does not affect TPC function.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Figure S1. Sorting of CD24highCD44lowEPCAMhigh tumor propagating cells.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Figure S1. Sorting of CD24highCD44lowEPCAMhigh tumor propagating cells.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Table S1. Key resources and reagents used in this study.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Table S1. Key resources and reagents used in this study.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from KSR1 Mediates Small Cell Lung Carcinoma Tumor Initiation and Cisplatin Resistance
The figure contains images of western blots of SCLC Cell lines used in the study
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from KSR1 Mediates Small Cell Lung Carcinoma Tumor Initiation and Cisplatin Resistance
The figure contains images of western blots of SCLC Cell lines used in the study
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from KSR1 Mediates Small Cell Lung Carcinoma Tumor Initiation and Cisplatin Resistance
Cisplatin dose response curves for SCLC cell lines with and without KSR1
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from KSR1 Mediates Small Cell Lung Carcinoma Tumor Initiation and Cisplatin Resistance
Cisplatin dose response curves for SCLC cell lines with and without KSR1